XOMA Corporation (NASDAQ:XOMA) has been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $12.00.
A number of research analysts recently issued reports on XOMA shares. HC Wainwright started coverage on XOMA Corporation in a report on Monday, June 12th. They set a “buy” rating and a $15.00 target price on the stock. Zacks Investment Research raised XOMA Corporation from a “sell” rating to a “hold” rating in a report on Thursday, March 23rd. Finally, Wedbush reaffirmed a “neutral” rating and set a $9.00 target price (down from $14.00) on shares of XOMA Corporation in a report on Monday, March 27th.
In related news, Director John Varian sold 39,540 shares of the stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $6.24, for a total value of $246,729.60. Following the completion of the transaction, the director now owns 2,344 shares in the company, valued at approximately $14,626.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.92% of the company’s stock.
A hedge fund recently bought a new stake in XOMA Corporation stock. Stonepine Capital Management LLC purchased a new position in shares of XOMA Corporation (NASDAQ:XOMA) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 87,960 shares of the biotechnology company’s stock, valued at approximately $625,000. XOMA Corporation accounts for 0.4% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 19th largest position. Stonepine Capital Management LLC owned approximately 1.17% of XOMA Corporation at the end of the most recent reporting period. Hedge funds and other institutional investors own 31.22% of the company’s stock.
XOMA Corporation (NASDAQ:XOMA) traded up 0.14% during midday trading on Friday, hitting $6.98. 46,954 shares of the company traded hands. XOMA Corporation has a 12-month low of $3.96 and a 12-month high of $13.98. The stock has a 50 day moving average of $6.58 and a 200 day moving average of $5.84. The stock’s market cap is $52.94 million.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286036/brokerages-set-xoma-corporation-xoma-pt-at-12-00.html
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.